Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price was down 2.4% on Thursday . The stock traded as low as $11.37 and last traded at $11.37, with a volume of 120,602 shares changing hands. The stock had previously closed at $11.65.

Several equities analysts have weighed in on VNDA shares. Jefferies Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Friday, June 10th. Brean Capital reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, June 6th. Canaccord Genuity reissued a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a report on Monday, March 14th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $15.92.

The company’s market cap is $494.96 million. The stock has a 50 day moving average of $10.83 and a 200-day moving average of $9.08.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. During the same period last year, the firm posted ($0.10) earnings per share. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $32.48 million. Vanda Pharmaceuticals’s revenue was up 50.0% on a year-over-year basis. Analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.83) EPS for the current year.

An institutional investor recently raised its position in Vanda Pharmaceuticals stock. J. Goldman & Co LP increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, Holdings Channel reports. The firm owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals comprises about 0.9% of J. Goldman & Co LP’s investment portfolio, making the stock its 25th largest position. J. Goldman & Co LP owned about 2.11% of Vanda Pharmaceuticals worth $8,405,000 as of its most recent filing with the SEC.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.